CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, announces the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. Under the terms of the agreement, CareDx received $171.2 million in cash consideration at closing, subject to customary post-closing adjustments.
Read the full article: CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific //
Source: https://www.businesswire.com/news/home/20260630207907/en/CareDx-Announces-Completion-of-Sale-of-Lab-Products-Business-to-Eurobio-Scientific